Evidence map›Paper›PMID 41377339›Full record

ArticleAnnals of medicine and surgery (2012)2025

Bupropion-induced tinnitus after dose escalation: a rare and reversible adverse effect - a case report.

Nalika Pathak, Susmita Khadka Chhetri, Dipesh Kumar Singh, Sanjeev Kumar Mishra

Abstract readCase Reports
In one paragraph

Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nalika PathakB.P. Koirala Institute of Health Sciences, Dharan, Nepal.
Susmita Khadka ChhetriB.P. Koirala Institute of Health Sciences, Dharan, Nepal.
Dipesh Kumar SinghB.P. Koirala Institute of Health Sciences, Dharan, Nepal.ORCID https://orcid.org/0009-0002-0785-727X
Sanjeev Kumar MishraDepartment of Psychiatry, B.P. Koirala Institute of Health Sciences, Dharan, Nepal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction and Importance: Bupropion is a norepinephrine-dopamine reuptake inhibitor commonly prescribed for major depressive disorder and smoking cessation. It is preferred for its minimal serotonergic activity and favorable side effect profile. However, rare adverse events such as tinnitus - the perception of sound without an external source - have been occasionally reported. Case Presentation: We report a 45-year-old male treated for depression with bupropion 150 mg/day, who developed bilateral low-pitched humming tinnitus after the dose was increased to 300 mg/day. He had no history of ear disease, noise trauma, or ototoxic medication use. Physical examination, audiometry, and brain MRI were unremarkable. Following dose reduction, the tinnitus partially improved, and it completely resolved after stopping the drug. Discussion: The temporal correlation between dose escalation and tinnitus onset, along with symptom resolution after drug cessation and lack of alternative causes, suggests a probable adverse drug reaction. The exact mechanism remains uncertain but may involve altered dopaminergic or noradrenergic signaling within the auditory system. Only a few cases of bupropion-induced tinnitus have been documented, making this report a relevant addition to the limited literature. Conclusion: This case underscores the rarity, bilateral nature, and reversibility of bupropion-induced tinnitus. It highlights the importance of clinician vigilance, structured patient education during dose escalation, and timely intervention to prevent unnecessary morbidity. As this is a single case report, broader clinical studies are warranted to substantiate causality and incidence. This case underscores the importance of clinician awareness regarding bupropion-induced tinnitus, particularly at higher doses. The rarity and reversibility highlight the need for vigilance, patient education during dose escalation, and timely dose adjustment or discontinuation. Limitations include the single-case design and possible confounders such as comorbid anxiety.

Indexed as

antidepressantbupropiontinnitus

Identifiers

PMID41377339
PMCPMC12688901

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.